Altered neurotransmitters in cerebrospinal fluid of children with autism spectrum disorder.

Researchers studied brain fluid from 8 children with autism and 9 children without autism to look for differences in brain chemicals. They found that children with autism had lower levels of three important brain chemicals (glutamine, norepinephrine, and kynurenine) compared to other children. This suggests that problems with these brain chemicals might be connected to autism symptoms. The study is small but could help scientists better understand what causes autism.

This exploratory study examined neurotransmitter levels in cerebrospinal fluid (CSF) samples from 8 children with autism spectrum disorder and 9 typically developing controls using liquid chromatography-tandem mass spectrometry. The research aimed to identify potential biomarkers for ASD by analyzing neurotransmitter concentrations in CSF, which directly reflects brain chemistry. Results showed significantly lower levels of glutamine, norepinephrine, and kynurenine in children with ASD compared to controls. The findings suggest dysregulation in the glutamine-glutamate cycle, which is important for brain function and may contribute to core autism symptoms.

While preliminary, this research provides insights into potential neurobiological mechanisms underlying ASD and suggests these neurotransmitters could serve as biomarkers for the condition.

Findings suggest potential biomarkers for ASD but require validation in larger, diverse populations before clinical application. The invasive nature of CSF collection limits practical implementation. Results may inform future therapeutic targets focusing on neurotransmitter pathways, particularly glutamine-glutamate systems.

Very small sample size (8 ASD, 9 controls) limits generalizability. Single-center study with no replication. CSF collection is invasive and may not be feasible for routine clinical use. No information provided about participant characteristics, age ranges, or potential confounding factors.

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by social deficits and repetitive behaviors. Neurotransmitter imbalances have been implicated in ASD, but few studies have examined cerebrospinal fluid (CSF) alterations in ASD patients. Identifying specific CSF biomarkers could enhance our understanding of the underlying neurobiology and improve diagnostic and therapeutic approaches. CSF samples were collected from 17 children, including 8 with ASD and 9 typically developing controls.

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to analyze neurotransmitter levels and metabolites in the CSF samples. Statistical comparisons were performed to identify group differences in neurotransmitter concentrations. ASD participants had significantly lower levels of glutamine, norepinephrine, and kynurenine compared to controls. Neurotransmitter dysregulation, particularly in the glutamine-glutamate cycle, was observed in ASD, potentially contributing to core symptoms.

Our findings suggest that neurotransmitter imbalances in the CSF could serve as potential biomarkers for ASD. Further research is needed to validate these findings and explore therapeutic interventions targeting these neurotransmitter pathways.